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Abstract An antagonistic activity against vascular endothelial
growth factor (VEGF) was identified in the culture supernatants
of certain human hematopoietic cell lines and the antagonistic
protein was purified from NALM-16 (B cell) culture super-
natant. Amino acid sequencing of the N-terminus and Western
blot analysis confirmed that the antagonist was identical to a
soluble truncated form of Flt-1 (sFlt-1). Seventeen of 52
leukemia and lymphoma cell lines investigated expressed sFlt-1
mRNA, and 16 of the sFlt-1 expressing cells also expressed
VEGF and membrane-bound Flt-1 (mFlt-1). This report is the
first showing that sFlt-1 can be produced by malignant
hematopoietic cells, suggesting that the production of VEGF
antagonist by hematopoietic cells may play some role in the
regulation of VEGF activity in normal and malignant hemato-
poietic cell proliferation.
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1. Introduction
Vascular endothelial growth factor (VEGF), also known as
vascular permeability factor, is a multifunctional cytokine that
regulates angiogenesis, vasculogenesis and in£ammation [1].
VEGF is widely expressed in normal tissues as well as in
cultured human umbilical vein endothelial cells (HUVEC)
[2]. A variety of solid tumors are also known to secrete
VEGF as an important mediator of angiogenesis to support
their growth in vivo and up-regulation of VEGF production is
generally observed in tumor cells under hypoxic conditions
[3]. VEGF exerts its biological function through high a⁄nity
tyrosine kinase receptors such as Flt-1 (fms-like tyrosine ki-
nase 1) [4], and Flk-1 [5]/KDR [6] (fetal liver kinase 1, or
kinase domain-containing receptor). Recent studies showed
that a number of hematopoietic cells expressed VEGF as
well as its receptors, indicating autocrine or paracrine growth
mechanisms for hematopoietic cells [7,8].
Kendall et al. [9] reported that the mRNA for a soluble
truncated form of Flt-1 (sFlt-1) was generated by alternative
splicing in HUVEC and that recombinant sFlt-1 inhibited
the mitogenic activity of VEGF on HUVEC by functioning
as a competitive inhibitor. They also showed sFlt-1 to be a
naturally produced antagonist after purifying the endogenous
sFlt-1 protein from HUVEC cultures. When expressed in tu-
mor cells by gene transfection, sFlt-1 was also shown to have
in vivo antitumor activity [10]. Recombinant soluble Flk-1/
KDR was also examined for its antitumor activity and was
shown to be e¡ective by functioning as a dominant-negative
inhibitor for VEGF-induced angiogenesis [11]. However, a
natural form of soluble Flk-1/KDR has not yet been identi¢ed.
In this study, we investigated the possibility that hemato-
poietic malignant cell lines produce a factor antagonistic to
VEGF and found that sFlt-1 was produced by NALM-16, a B
cell line derived from a patient with acute lymphoblastic leu-
kemia [12]. Production of sFlt-1 protein has been reported in
HUVEC cultures, but not in malignant hematopoietic cells or
other cell types. To the best of our knowledge, our study is
the ¢rst to show that functional sFlt-1 is produced by hema-
topoietic cells.
2. Materials and methods
2.1. Preparation of cell culture supernatants
Cell culture supernatants were prepared from 52 hematopoietic cell
lines maintained in our center. Cells were cultured in RPMI 1640 me-
dium (Nissui, Tokyo, Japan) supplemented with 10% heat-inactivated
fetal bovine serum (FBS, Gibco, New York, USA), 100 U/ml of
penicillin and 50 Wg/ml of streptomycin at 37‡C in a humidi¢ed 5%
CO2/air mixture. The cells were harvested and seeded at a density of
2U106 cells/ml in 10 ml of fresh medium. After 3 days of culture
under the same conditions, the supernatants were collected, and
used as samples for screening VEGF antagonist producing cells.
2.2. VEGF inhibition assay
The human gastric cancer cell line KATO-III, which produces a
high level of VEGF under hypoxic conditions, was used in our
VEGF inhibition assay. The cells cultured in 10% FBS^RPMI
1640 medium at 37‡C in a humidi¢ed 5% CO2/air mixture were har-
vested and suspended in fresh medium at a density of 5U104cells/ml.
200 Wl of the cell suspension and 50 Wl of the sample for screening
were mixed in the wells of 96 well plates and incubated at 37‡C in a
multiple gas incubator (MCO-175M, Sanyo Electric, Tokyo, Japan)
with humidi¢ed nitrogen gas containing 2% O2 and 5% CO2. After
24 h, the supernatant was harvested and its VEGF content was meas-
ured by ELISA (RpD Systems, Minnesota, USA). The inhibition of
the rate of VEGF production was calculated by the following equa-
tion: Inhibition (%) = (13VEGF production with sample/VEGF pro-
duction without sample)U100.
2.3. Puri¢cation of VEGF antagonist
To purify the VEGF antagonist, culture supernatants of NALM-16
cells were prepared on a large scale. The cells were grown in 10%
FBS^RPMI 1640 medium and were transferred to 2 l of FBS-free
RPMI 1640 medium at a density of 2U106 cells/ml in a 5 l spinner
bottle. After 3 days of culture at 120 rpm, the supernatant was col-
lected and used as the starting material for the puri¢cation procedure.
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A total of 20 l of NALM-16 cell culture supernatant was concentrated
40-fold by UF module (AIL1010, Asahi Kasei, Tokyo, Japan) and
dialyzed against 10 mM phosphate bu¡er (pH 7.4) containing 0.1%
polyethylene glycol (PEG) and 0.05% NaN3 using the same module.
As a primary step, the activity was puri¢ed on a Macro prep ceramic
hydroxyapatite type 1 column (26 mm diameterU300 mm, bed vol-
ume 160 ml, Bio-Rad, Hercules, CA, USA). Fractions with the de-
sired activity were pooled, concentrated, and dialyzed against 20 mM
Tris^HCl bu¡er (pH 7.4) containing 0.1% PEG and 0.05% NaN3. As
the next step, pooled activity-containing fractions from hydroxyapa-
tite column chromatography were further puri¢ed by Heparin-5PW
column chromatography (7.5 mm diameterU75 mm, bed volume 3.3
ml, Tosoh, Tokyo, Japan). The fractions exhibiting antagonist activity
were again pooled, concentrated, and dialyzed against PBS containing
0.1% PEG and 0.05% NaN3. Furthermore, culture supernatant of
P30/OHKUBO cells, a B cell line derived from a patient with acute
lymphoblastic leukemia [13] and positive for VEGF antagonist activ-
ity, was puri¢ed on the same hydroxyapatite column under conditions
similar to that of the NALM-16 supernatant.
2.4. Molecular weight estimation by SDS^PAGE gel extraction assay
The puri¢ed sample obtained after Heparin-5PW column chroma-
tography was separated in 7% SDS^PAGE gel under non-reducing
conditions and the antagonist activity was monitored after elution
from the gel.
2.5. N-terminal amino acid sequence analysis
The puri¢ed sample was applied to an SDS^PAGE gel, and then
electroblotted onto a polyvinylidene di£uoride (PVDF) membrane
(0.2 Wm; Bio-Rad). The blotting was carried out at 25 V for 2 h at
4‡C in a 10 mM CAPS, 10% methanol bu¡er (pH 11). The protein
was stained with Coomassie brilliant blue (CBB-1, Wako, Osaka,
Japan), and the protein bands were cut out and subjected to amino
acid sequence analysis on a gas phase protein sequencer (Applied
Biosystems, California, USA).
2.6. Western blotting analysis
The culture supernatants of NALM-16 and P30/OHKUBO cells
puri¢ed by hydroxyapatite column chromatography were applied to
SDS^PAGE, and blotted onto a PVDF membrane. These were
probed with a polyclonal goat anti-human Flt-1 antibody (RpD Sys-
tems) to detect Flt-1. A secondary antibody conjugated to horseradish
peroxidase and an enhanced chemoluminescence (ECL) kit (Amer-
sham, Buckinghamshire, UK) were used for detection.
2.7. Scatchard analysis of VEGF binding to sFlt-1
The speci¢c binding of VEGF to sFlt-1 was evaluated by Scatchard
analysis. Puri¢ed sFlt-1 was prepared from both NALM-16 cells and
HUVEC (Kurabo Biomedical, Osaka, Japan) culture supernatants by
two-step chromatography, and were coated onto the surface of 96 well
plates (20 ng/well) for 16 h at 4‡C. After blocking the remaining
protein binding sites of the wells with 0.5% gelatin, 50 Wl of an in-
creasing concentration of 125I-labeled VEGF (Amersham) was added
to the wells. After 2 h incubation at room temperature, the free
VEGF was washed out by rinsing with PBS. Each well was then
individually counted for the binding radioactivities by Q counter (Alo-
ka, Tokyo, Japan). Non-speci¢c binding was calculated as the VEGF
binding to a well with no sFlt-1 coating.
2.8. Reverse transcription polymerase chain reaction (RT-PCR)
The expression of VEGF, sFlt-1, and mFlt-1 was analyzed at the
mRNA level by RT-PCR. Cytoplasmic RNA was extracted from
cultured cells using Ultraspec RNA isolation system (Biotecx Labo-
ratories, Texas, USA). 1 Wg of puri¢ed total RNA was used to syn-
thesize the ¢rst strand cDNA applying reverse transcriptase preampli-
¢cation using random primer, 100 pmol in 30 Wl. The RT was carried
out in a ¢nal volume of 30 Wl of RT bu¡er (50 mM Tris^HCl, pH 8.4,
75 mM KCl, 3 mM MgCl2, 0.1 mg/ml bovine serum albumin). The
mixture was incubated at 65‡C for 15 min. Then 200 U of RT, 1 Wl of
25 mM dNTP mix, 6.7 mM DTT and 20 U of RNase inhibitor were
added to the reaction, which was incubated at 37‡C for 60 min. 2 Wl of
the ¢rst strand cDNA was diluted with PCR bu¡er (10U500 mM
KCl, 15 mM MgCl2, 100 mM Tris^HCl, pH 8.8, 0.01% gelatin) con-
taining 30 pmol sense and antisense primer, 15 nmol of dNTP mix
and 1.5 U of Taq DNA polymerase. The primers were prepared ac-
cording to published data and were:
Antisense primers for sFlt-1 and mFlt-1 were designed to target
alternatively spliced sFlt-1 mRNA and mFlt-1 mRNA, respectively.
PCR was performed under the following conditions: VEGF:
35 cycles of denaturation for 1 min at 94‡C, annealing for 1 min at
55‡C, extension for 1 min at 72‡C; sFlt-1 and mFlt-1: 35 cycles of
denaturation for 1 min at 94‡C, annealing for 2 min at 58‡C, exten-
sion for 4 min at 72‡C.
3. Results and discussion
3.1. Antagonistic activity detected in culture supernatants
From the 52 hematopoietic cell lines tested, the superna-
tants of two cell lines, NALM-16 and P30/OHKUBO, were
shown to reduce VEGF production in KATO-III cell cultures
by 34 and 30% respectively. Furthermore, these supernatants
VEGF: sense 5P-TTCTGTATCAGTCTTTCCTGGTGAG-3P
antisense 5P-CGAAGTGGTGAAGTTCATGGATG-3P
sFlt-1: sense 5P-GCACCTTGGTTGTGGCTGAC-3P
antisense 5P-CAACAAACACAGAGAAGG-3P
mFlt-1: sense 5P-GCACCTTGGTTGTGGCTGAC-3P
antisense 5P-CGTGCTGCTTCCTGGTCC-3P
Fig. 1. Puri¢cation of VEGF antagonist by two-step chromatogra-
phy. A: Concentrated NALM-16 cell culture supernatant was ap-
plied to a hydroxyapatite column (26 mm diameterU300 mm, bed
volume 160 ml) previously equilibrated with 10 mM phosphate bu¡-
er (pH 7.4) containing 0.1% PEG and 0.05% NaN3. The column
was washed with the same bu¡er, and eluted with a linear gradient
of 10^500 mM phosphate bu¡er (pH 7.4) containing 0.1% PEG and
0.05% NaN3 at a £ow rate of 8 ml/min. Sample with VEGF antag-
onist activity was eluted at phosphate concentrations between 340
to 480 mM. These were pooled, concentrated, and dialyzed against
20 mM Tris^HCl bu¡er (pH 7.4) containing 0.1% PEG and 0.05%
NaN3. B: Pooled fractions with antagonist activity after hydroxy-
apatite column chromatography were applied to a Heparin-5PW
column (7.5 mm diameterU75 mm, bed volume 3.3 ml) previously
equilibrated with 20 mM Tris^HCl bu¡er (pH 7.4) containing 0.1%
PEG and 0.05% NaN3. The column was washed with the same bu¡-
er, and eluted with a linear gradient of 0^2 M of NaCl in the same
bu¡er at a £ow rate of 0.5 ml/min. One active peak detected be-
tween NaCl concentrations of 1.12 and 1.30 M separated from ma-
jor protein peaks.
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inhibited VEGF-dependent growth of HUVEC (data not
shown). However, it was still not clear whether the superna-
tants contained an inhibitor of VEGF production by the
KATO-III cells or they contained a VEGF antagonist.
When the supernatants were mixed with recombinant
VEGF, the amount of VEGF detected by ELISA was found
to decrease signi¢cantly, indicating the presence of VEGF-
speci¢c antagonist in the culture supernatant. Therefore, we
used a direct inhibition assay based on ELISA instead of an
inhibition assay based on VEGF production by KATO-III
cells for further puri¢cation of the activity.
3.2. Puri¢cation of VEGF antagonist
Approximately 20 l of FBS-free culture supernatant of
NALM-16 cells was used for puri¢cation of the VEGF antag-
onist. Two-step column chromatography using hydroxyapa-
tite and Heparin-5PW was performed as shown in Fig. 1.
The speci¢c activity increased 3.8 times after hydroxyapatite
chromatography and another 86 times after Heparin-5PW
chromatography. Puri¢ed proteins with high speci¢c activity
in the Heparin-5PW fractions amounted to 815 Wg and a
pooled sample was used for molecular weight determination
by SDS^PAGE. The protein staining pattern of an SDS^
PAGE gel is shown in Fig. 2 together with the antagonist
activity pro¢le of protein extracts from 2 mm gel slices. A
major activity band was located at a molecular weight of
100 kDa. At the corresponding position, a broad protein
band was identi¢ed in the gel and this was used for further
N-terminal sequence analysis. A fraction with minor activity
was also identi¢ed between 130 and 160 kDa. Since we could
not detect any protein band at the corresponding position, we
did not analyze this fraction any further.
3.3. Identi¢cation of VEGF antagonist as sFlt-1
We next tried to identify the VEGF antagonist by N-termi-
nal amino acid analysis and Western blotting. Although we
did not determine the C-terminal sequence of the VEGF an-
tagonist protein in NALM-16 cell culture supernatants, we
concluded that this protein was sFlt-1 on the basis of the
following. (1) Of 21 analyzed N-terminal amino acids, except
for ¢ve unidenti¢ed amino acid residues, 16 amino acid resi-
dues completely matched those of a sequence in human Flt-1
[9] (Fig. 3). (2) An antibody recognizing the extracellular do-
main of human Flt-1 reacted with a 100 kDa band in the
protein puri¢ed from NALM-16 culture supernatants (Fig.
4), but an antibody recognizing the cytoplasmic region did
not react with the antagonist (data not shown). (3) The mo-
lecular mass is in good agreement with that of human sFlt-1
as described previously. (4) Alternatively spliced sFlt-1
mRNA was detected by RT-PCR in NALM-16 cells (Fig.
5). (5) The antagonist was detected in the culture supernatant.
Fig. 2. Molecular weight estimation of VEGF antagonist by gel ex-
traction analysis. The protein sample obtained after two-step col-
umn chromatography was separated on 7% SDS^PAGE gel under
non-reducing conditions. The gel was sliced into 2 mm pieces, and
soaked in 200 Wl of 10% FBS^RPMI 1640 medium for 18 h at 4‡C.
The gel extracts were dialyzed against the RPMI 1640 medium, and
were examined for VEGF antagonist activity. The molecular weight
of the fraction showing activity was estimated against mobility of
protein standards. The positions of molecular weight standards are
indicated by arrows. The gel after silver staining is shown above the
activity pro¢le. One activity peak at 100 kDa corresponded to a
major protein band present in the gel.
Fig. 3. Amino acid sequence comparison between VEGF antagonist
isolated from NALM-16 cells and human Flt-1. The protein show-
ing up as a 100 kDa band obtained as described in the legend for
Fig. 2 was used for N-terminal amino acid sequence analysis.
Twenty-one amino acids from the N-terminus were analyzed and
are shown in alignment with a sequence from human Flt-1. The hu-
man Flt-1 sequence was obtained from GenBank database
(NP_002010). X designates unidenti¢ed amino acid residues.
Fig. 4. Detection of sFlt-1 by Western blotting. VEGF antagonists
puri¢ed from the culture supernatant of NALM-16 and P30/OH-
KUBO cells were blotted onto a PVDF membrane, and incubated
with polyclonal anti-human Flt-1 antibody. The antibody recognizes
the extracellular portion of Flt-1. The strong Flt-1 bands derived
from NALM-16 and P30/OHKUBO cells corresponded to a molecu-
lar weight between 90 and 110 kDa (indicated by rectangular bar).
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3.4. Scatchard analysis
We further analyzed whether sFlt-1 derived from NALM-
16 cells could really bind to VEGF. The sFlt-1 proteins from
NALM-16 cell and HUVEC culture supernatants were com-
pared by Scatchard analysis using 125I-labeled VEGF. As
shown in Fig. 6, sFlt-1 derived from NALM-16 bound to
VEGF with high a⁄nity as in the case of HUVEC. Therefore,
we concluded that sFlt-1 obtained from NALM-16 cells can
act as a VEGF antagonist by directly binding to VEGF.
3.5. Expression of Flt-1 and VEGF in other hematopoietic cell
lines
We next examined sFlt-1 expression in other hematopoietic
cell lines. sFlt-1 protein was detected in P30/OHKUBO cul-
ture supernatant by Western blotting analysis (Fig. 4). As for
other cell lines, we investigated sFlt-1 mRNA expression as
well as that of mFlt-1 and VEGF by RT-PCR. Fifty-two cell
lines representing the main hematopoietic lineages including
T, B, myeloid, monocytoid, megakaryocytic, and erythroid
cells were analyzed, and the results are summarized in Table
1. Seventeen cell lines expressed sFlt-1 while 32 expressed
mFlt-1. As an example of mRNA expression pro¢le, the ex-
pression of ¢ve representative cell lines is shown in Fig. 5.
Nearly all cell lines (90%) expressed VEGF mRNA. There is
no apparent correlation between the expression of sFlt-1 and
a particular cell lineage. When cells expressed sFlt-1 mRNA,
mFlt-1 mRNA was always simultaneously expressed.
Among the 17 cell lines expressing sFlt-1 mRNA, we iden-
ti¢ed only two cell lines with VEGF antagonist activity in the
Fig. 5. RT-PCR detection of sFlt-1, mFlt-1 and VEGF mRNA in
hematopoietic cell lines. Expression of sFlt-1 (A), mFlt-1 (B) and
VEGF (C) was analyzed at mRNA level by RT-PCR. Results of
¢ve di¡erent cell lines are shown. NALM-16 and KE-37 expressed
both sFlt-1 and mFlt-1 mRNA (lanes 1 and 5). NAMALWA ex-
pressed mFlt-1 but not sFlt-1 (lane 3). C5/MJ and BJAB were nega-
tive for both sFlt-1 and mFlt-1 mRNA (lane 2 and 4). VEGF
mRNA was detected in all ¢ve cell lines. Another 47 cell lines were
also examined in the same way and results are summarized in Table
1.
Fig. 6. Scatchard analysis. Puri¢ed sFlt-1 derived from NALM-16
cells (A) or HUVEC (B) were coated onto the surface of 96 well
plates. Increasing concentrations of 125I-labeled VEGF were added
to each well and speci¢c binding was counted by Q counter. The
analysis showed that sFlt-1 derived from both NALM-16 cells and
HUVEC acts as a high-a⁄nity VEGF receptor. Dissociation con-
stant are shown in the boxes.
Table 1
The expression of the mRNA for VEGF, its receptor sFlt-1, and mFlt-1 by representative hematopoietic cell lines
Cell phenotype Number of cells tested Number of cells positive for
VEGF sFlt-1 mFlt-1
T cell 19 18(95%) 7(37%) 12(63%)
B cell 24 21(88%) 9(38%) 15(63%)
Myeloid 5 4(80%) 0(0%) 3(60%)
Monocytoid 2 2(100%) 1(50%) 1(50%)
Megakaryocytic 1 1(100%) 0(0%) 0(0%)
Erythroid 1 1(100%) 0(0%) 1(100%)
Total 52 47(90%) 17(33%) 32(62%)
Figures in parentheses show the percentage of positive cell lines representing that lineage.
FEBS 23389 29-2-00
T. Inoue et al./FEBS Letters 469 (2000) 14^18 17
culture supernatants. This may possibly be explained partly by
absence of expression of sFlt-1 at the protein level in the
sFlt-1 mRNA-positive but antagonist activity-negative cell
lines. However, there is another possible explanation based
on the above ¢nding that most of the sFlt-1 expressing cell
lines also expressed VEGF mRNA. The simultaneous produc-
tion of sFlt-1 and VEGF would probably result in neutraliza-
tion of antagonist activity in the cell culture supernatants. To
examine this hypothesis, we performed Western blotting using
four of the 15 sFlt-1 mRNA-positive cell lines whose super-
natant showed negative antagonistic activity. As shown in
Fig. 7, none of them expressed detectable amounts of sFlt-1
at the protein level, supporting the ¢rst hypothesis.
VEGF and its receptors play pivotal roles in endothelial cell
functions, such as angiogenesis, vasculogenesis, and permea-
bilization of blood vessels. Furthermore, VEGF has been
shown to have a number of e¡ects on hematopoietic cells,
such as regulation of early hematopoietic cell proliferation
[8], autocrine proliferation of malignant cells [14], maturation
of dendritic cells [15], and the protection of stem cells from
apoptosis [16]. Our study suggests that the production of
sFlt-1 as a VEGF antagonist by hematopoietic cells may
play some regulatory roles in VEGF activity in normal and
malignant hematopoietic cells.
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Fig. 7. Western blotting of sFlt-1. Supernatants of NALM-16 and
four other cell lines which express sFlt-1 mRNA but did not show
VEGF antagonist activity were used for partial puri¢cation of sFlt-
1. Hydroxyapatite column fractions corresponding to the active
fraction of NALM-16 culture supernatants were pooled, concen-
trated, and dialyzed against PBS. Detection of sFlt-1 was performed
by Western blotting as described in Fig. 4. None of these four cell
lines with no VEGF antagonist activity expressed detectable
amounts of sFlt-1 protein.
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